NCT00612963

Novel Rinse to Treat in Oral Candidiasis in Cancer Patients

Novel Rinse to Treat Oral Candidiasis in Cancer Patients "Evaluate Iocide Oral Rinse in Any Patient With Thrush, Including But Not Limited to Patients Currently Receiving or Post Radiation Therapy for Head and Neck Cancer or Patients Positive for HIV/AIDS or Transplant Patients"

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 23 (actual)
• Sponsor: Biomedical Development Corporation · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received radiation therapy for head and neck cancer, or patients positive for HIV/AIDS or are transplant patients.

Detailed description

A four-week study has been designed as an assessment of the clinical cure and mycological eradication of oral Candida isolates in 40 cancer patients referred by radiation oncologists during the course of his/her treatment. An estimated 35 patients will be evaluable at the end of the study. Candida infection is defined as positive clinical signs (white plaques) with positive potassium hydroxide (KOH) preparation and positive cultures. Colonization is defined as a positive culture without signs of clinical infection.

Conditions

• Candidiasis, Oral
• Thrush
• Candidiasis

Interventions

Type	Name	Description
DRUG	Frio Oral Rinse	Prescription Mouth Rinse

Timeline

• Start date: 2007-04-01
• Primary completion: 2009-05-01
• Completion: 2009-05-01
• First posted: 2008-02-12
• Last updated: 2010-03-08

Locations

2 sites across 1 country: United States